About the Company
We do not have any company description for NKGen Biotech, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on NKGen Biotech, Inc.
NKGen Biotech, Inc. to Become Publicly Traded Company via ... - Nasdaq
--NKGen Biotech, Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK Natural Killer cell therapeutics, and ...
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial ... - Nasdaq
--NKGen Biotech Inc., a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics ...
NKGen Biotech, Inc. Announces First Patient Dosed in Phase I Clinical ...
SANTA ANA, Calif., Aug. 24, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization ...
NKGen Biotech, Inc. Announces Closing of Business Combination
Company to Commence Trading on Nasdaq under Ticker Symbol “NKGN” on Monday, October 2, 2023SANTA ANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (“NKGen” or the ...
NKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a ...
NKGen Biotech, Inc. is developing SNK01 for the treatment of neurodegenerative disorders and a broad range of cancers. About NKGen ...
NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC ...
NKGen Biotech, Inc. (“NKGen” or the “Company”) has regained compliance on its public reporting obligations with the filing of its most recent quarterly report on Form 10-Q on March 4, 2025 ...
NKGen Biotech, Inc. to Become Publicly Traded Company via Business ...
NKGen Biotech, Inc. (“NKGen”), a clinical stage Natural Killer (NK) cell therapy company, has entered into a merger agreement with Graf Acquisition Corp. IV NKGen Biotech, Inc.’s non ...
NKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and ...
SANTA ANA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- NKGen Biotech Inc. (Nasdaq: NKGN) (NKGen or the Company), a clinical-stage biotechnology company focused on the development and ...
Similar Companies
Loading the latest forecasts...